To investigate the efficacy of fingolimod at the approved 0.5 mg dose in patients early in the MS disease course , post hoc subgroup analyses of TRANSFORMS ( n = 272 ) and FREEDOMS ( n = 217 ) data were conducted in patients who experienced their first MS symptom < 3 years before randomization .